Fatal venous thromboembolism after splenectomy: Pathogenesis and management

Journal of the American Osteopathic Association

Volumn 112, Issue 5, 2012, Pages 291-300

  Ha, Linda P ^a   Arrendondo, Mark ^a  

^a Internal Medicine Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ADULT; CASE REPORT; FATALITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PATHOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; RISK FACTOR; SPLENECTOMY; THROMBOCYTOPENIA; TIME; VENOUS THROMBOEMBOLISM;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; FATAL OUTCOME; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROTEIN C; PROTEIN S; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; SPLENECTOMY; THROMBOCYTOPENIA; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84861140181     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Geerts WH, Bergqvist D, Pineo G, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
2. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: Evidence-Based Clinical Practice Guidelines (8th Edition) [published correction appears in Chest. 2008;134(4):892]. Chest. 2008;133(6 suppl):454S-545S.
3. Hospital-acquired conditions (present on admission indicator). Centers for Medicare and Medicaid Services. http://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html?redirect=/HospitalAcqCond/06_Hospital-Acquired_Conditions.asp. Accessed April 5, 2012.
4. Office of the Surgeon General. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Washington, DC: US Department of Health and Human Services; 2008.
5. National Quality Forum. Measure 0218: Surgery patients who received venous thromboembolism (VTE) prophylaxis within 24 hours prior to surgery to 24 hours after surgery end time. National Quality Forum Web site. http://www.qualityforum. org/QPS/0218. Accessed April 25, 2012.
6. National Quality Forum. Measure 0371: Venous thromboembolism (VTE) prophylaxis. National Quality Forum Web site. http://www.qualityforum.org/QPS/0371. Accessed April 25, 2012.
7. National Quality Forum. Measure 0239: Venous thromboembolism (VTE) prophylaxis. National Quality Forum Web site. http://www.qualityforum.org/QPS/0239. Accessed April 25, 2012.
8. National Quality Forum. Measure 0376: Incidence of potentially preventable VTE. National Quality Forum Web site. http://www.qualityforum.org/QPS/0376. Accessed April 25, 2012.
9. National Quality Forum. Measure 0434: Venous thromboembolism (VTE) prophylaxis. National Quality Forum Web site. http://www.qualityforum.org/QPS/0434. Accessed April 25, 2012.
10. Mukherjee D, Lidor AO, Chu KM, Gearhert SL, Haut ER, Chang DC. Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surg. 2008;12(11):2015-2022.
11. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in acute hospital care setting (ENDORSE study): multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
12. Muntz J. Duration of deep vein thrombosis prophylaxis in the surgical patient and its relation to quality issues. Am J Surg. 2010;200(3):413-421.
13. Schackford S, Roger FB, Terrein CM, Bouchard P, Ratliff J, Zubis R. A 10-year analysis of venous thromboembolism on the surgical services: the effect of practice guidelines for prophylaxis. Surgery. 2008;144(1):3-11.
14. McLeod RS, Geerts WH, Sniderman KW, et al; Canadian Colorectal Surgery DVT Prophylaxis Trial Investigators. Subcutaneous heparin versus low-molecularweight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg. 2001;233(3):438-444.
15. Spyropoulos AC, Brotman DJ, Amin AN, Deitelzweig SB, Jaffer AK, McKean SC. Prevention of venous thromboembolism in the cancer surgery patient. Cleve Clin J Med. 2008;75(suppl 3):S17-S26.
16. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099-1103.
17. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 suppl):132S-175S.
18. Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195S-e226S.
19. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):53S-70S. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421263/pdf/20010300s00020p438.pdf. Accessed April 5, 2012.
20. Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505. http://jco.ascopubs.org/content/25/34/5490.full.pdf. Accessed April 5, 2012.
21. Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schunemann HJ. Extended perioperative thromboprophylaxis in patients with cancer: a systematic review. Thromb Haemost. 2008;100(6):1176-1180.
22. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann NY Acad Sci. 2005;1054:317-324.
23. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol. 2004;76(2):143-147.
24. Mohamed SY, Abdel-Nabi I, Inam A, et al. Systemic thromboembolic complications after laparascopic splenectomy for idiopathic thrombocytopenia purpura in comparison to open surgery in the absence of anticoagulant prophylaxis. Hematol Oncol Stem Cell Ther. 2010;3(2):71-77.
25. Streiff MB, Bockenstedt PL, Cataland SR, et al. Venous thromboembolic disease. J Natl Compr Canc Netw. 2011;9(7):714-777. http://www.jnccn.org/content/9/7/714.full.pdf. Accessed April 5, 2012.
26. Patel MI, Hardman DT, Nicholis D, Fisher CM, Appleberg M. The incidence of deep venous thrombosis after laparascopic cholecystectomy. Med J Aust. 1996;164(11):652-654,656.
27. Schaepkens Van Riempst JT, Van Hee RH, Weyler JJ. Deep venous thrombosis after laparascopic cholecystectomy and prevention with nadroparin. Surg Endosc. 2002;16(1):184-187.
28. Ageno W, Manfredi E, Dentali F, et al. The incidence of venous thromboembolism following gynecologic laparascopy: a multicenter, prospective cohort study. J Thromb Haemost. 2007;5(3):503-506.
29. Beekman R, Crowther M, Farrokhyar F, Birch DW. Practice patterns for deep vein thrombosis prophylaxis in minimal-access surgery. Can J Surg. 2006;49(3):197-202.
30. Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res. 2008;122(5):599-603.
31. Lammers AJ, Veninga D, Lombarts MJ, Hoekstra JB, Speelman P. Management of post-splenectomy patients in the Netherlands. Eur J Clin Microbiol Infect Dis. 2010;29(4):399-405.
32. Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006;81(6):391-396.
33. Harris EN, Gharavi AE, Hedge U, et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol. 1985;59(2):231-234.
34. Lipp E, von Felten A, Sax H, Müller D, Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998;60(5):283-288.
35. Diz-Küçükkaya R, Hacihanefioglua, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760-1764.
36. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol. 2002;118(3):893-898.
37. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha A. Hemostatic alterations in splenectomized and non-splenectomized patients with thalassemia/hemoglobin E disease. Thromb Res. 2007;120(6):805-810.
38. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295-300.
39. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol. 1985;20(4):365-372.
40. Hirsh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thromboembolism: a consequence of continuing anaemia. Br J Haematol. 1966;12(1):44-53.
41. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and eythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassemic patients. Br J Haematol. 2002;118(3):893-898.
42. Ikeda M, Sekimoto M, Takiguchi S, et al. Total splenic vein thrombosis after laparascopic splenectomy: a possible candidate for treatment. Am J Surg. 2007; 193(1):21-25.
43. Arixtra (fondaparinux sodium injection) [prescribing information]. Glaxo-SmithKline Web site. http://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1244136744215&featureKey=600552. Accessed April 5, 2012.
44. van't Riet M, Burger JW, van Muiswinkel JM, Kazemier G, Schipperus MR, Bonjer H. Diagnosis and treatment of portal vein thrombosis following splenectomy. Br J Surg. 2000;87(9):1229-1233.
45. Lovenox (enoxaparin sodium injection) [prescribing information]. sanofi-aventis Web site. http://lovenox.com/hcp/dosing/surgery-dvt-prophylaxis.aspx. Accessed April 5, 2012.
46. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409-415.
47. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-422.
48. Rutherford RB. Prophylactic indications for vena cava filters: critical appraisal. Semin Vasc Surg. 2005;18(3)158-165.
49. Streiff MB. Vena cava filters: a review for intensive care specialists. J Intensive Care Med. 2003;19(2):59-79.
50. Chiou AC, Biggs KL, Matsumura JS. Vena cava filters: why, when, what, how? Pers Vasc Surg Endovasc Ther. 2005;17(4):329-339.
51. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Lowmolecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
52. Wallace MJ, Jean JL, Gupta S, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer. 2004;101(8):1902-1907.
53. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M; PEASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005;92(10):1212-1220.
54. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembollism in highrisk abdominal surgery. Drugs. 2002;62(15):2283-2314.
55. Gould MK, Garcia DA, Wren SH, et al. Prevention fo VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e227S-e277S.